Trade name : A bec
Active ingredient : Abacavir
Strength availability : 300mg
Manufactured by : Emcure
Package : 30 tablets in a container
A bec is a combination tablet that contains ingredients like Abacavir A bec is involved in the treatment of HIV-type I infection, it is used with other anti-retroviral medicines to control the infections. A bec is manufactured by Emcure and it is active against HIV viruses which effectively prevent it from progressing to AIDS.
A bec tablet is indicated for the treatment of HIV type I infection patients.
The recommended dose of A bec tablet is one tablet of Abacavir 600mg for adult to be taken orally as a single dose, either 300mg twice daily or 600mg once daily in combination with other anti-retroviral medicines with or without food. In pediatric dose: based on body weight The patient’s weights of 14 to < 20 administer 1 tablet of 300mg given as morning half tablet 150mg and evening half tablet 150mg ≥ 20 to < 25 administered one and half tablets given as morning half tablet of 150mg and evening 1 tablet of 300mg ≥ 25 administer 2 tablets of 600mg given as morning 1 tablet of 300mg and evening 1 tablet of 300mg
Abacavir is a nucleoside reverse transcriptase inhibitor (carboxylic synthetic nucleoside analogue), it has activity against human immunodeficiency virus type I. Abacavir is phosphorylated into an active metabolite carbovir triphosphate (deoxyguanosine 5’triphosphate) dGTP This active metabolite prohibits the action of reverse transcriptase by competing with dGTP and inserted into viral DNA The growth of viral DNA gets affected by insertion of nucleotide which causes lack of OH molecule. OH molecules are essential for the formation of 5’ to 3’ phosphodiester linkage which is responsible for chain elongation.
Absorption: After oral administration of tablet A bec, abacavir and is highly absorbed and its bioavailability occurs at 83% respectively
Distribution: Abacavir is highly bound to human plasma protein nearly 50%;
Abacavir metabolism occurred by alcohol dehydrogenase and glucuronyl transferase.
The abacavir half life of is 1.54±0.63 hours
Caution with if patients having; Hypersensitivity reactions, lactic acidosis, severe hepatomegaly with steatosis and exacerbations of hepatitis B Fat redistribution, myocardial infarction, hepatic impairment
Zalcitabine, it is not concomitant with A bec because the effect of lamivudine which is present in the drug and Zalcitabine are inhibits each other. HLA-B*5701 allele not co administered with abacavir due to anaphylactic reactions occurs If taking getting methadone maintenance therapy, with abacavir 600mg twice daily leads to increase the methadone clearance Ethanol blocks the ability of the kidney to eliminate the drug abacavir
A bec tablets are contraindicated in the patients having HLA-B 5701 allele Hypersensitivity reaction to components present in the product Severe hepatic impairment
A bec tablets are contraindicated in the patients having If patient not taken A bec Tablet, then the dose should be administered within the time The particular missed dose should be skipped and continue the next drug schedule
Fatal hypersensitivity reactions Lactic acidosis and severe hepatomegaly with steatosis Exacerbations of hepatitis B Hepatic decompensated in patients co-infected with HIV-I and hepatitis C Immune reconstitution syndrome Fat redistribution Myocardial infraction Some common side effects; Insomnia, depression, headache, fatigue, dizziness, rash, pyrexia, abdominal pain, abnormal pain, anxiety